AI & Medicine
Latest in AI & Medicine· Oct 23
Moderna is staking its cancer vaccine on a clinical claim Merck's Keytruda does not make: preventing tumor recurrence over years rather than shrinking existing tumors. The company needs sustained efficacy data to justify positioning as a preventive therapy rather than competing directly on immediate response rates. Success in this narrower lane offers different pricing power and patient populations than active treatment, but requires proof of durability that checkpoint inhibitors like Keytruda do not demand.
AI applications and limitations in medical diagnosis and healthcare practice.
6 events tracked
- Single source20 days ago
Moderna's immunotherapy must prove it prevents tumor recurrence, not just rival Keytruda
Moderna's cancer vaccine success hinges on preventing recurrence, not competing directly with Merck's Keytruda.
MarketWatch
- Reported by 2 outlets20 days ago
Cancer vaccine trials expand beyond melanoma to brain and pancreatic tumors
Merck and Moderna's melanoma vaccine shows clinical efficacy, advancing personalized cancer immunotherapy toward commercialization.
CNBC · The New York Times
- Single source22 days ago
Moderna to unveil Phase 3 cancer vaccine results this weekend
Moderna to release cancer vaccine trial results with significant implications for the company and oncology market.
MarketWatch
- Single source23 days ago
Wall Street analysts deploy Claude AI to design experimental drug
Wall Street researchers used Claude AI to design a drug, creating a new investment thesis around AI-assisted pharmaceutical development.
MarketWatch
- Single sourceabout 1 month ago
Person undergoes full-body scan for cancer detection at $499 cost
Consumer reports on commercial full-body cancer screening scan costing $499, raising questions about preventive imaging adoption and market demand.
MarketWatch
- Single sourceabout 1 month ago
Mexico adopts artificial intelligence to catch breast cancer sooner
Mexico deploys AI technology to improve early breast cancer detection rates.
Al Jazeera